GEVA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical mean in terms of Price/Sales Ratio. The reason we use P/S Ratio instead of P/E Ratio or P/B Ratio is because Price/Sales Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median P/S Value is calculated as trailing twelve months (TTM) revenue per share times 10-Year median P/S ratio. Synageva BioPharma Corp's revenue per share for the trailing twelve months (TTM) ended in Mar. 2015 was $0.18. Synageva BioPharma Corp's 10-Year median P/S ratio is 14.37. Therefore, the Median P/S Value for today is $2.59.
As of today, Synageva BioPharma Corp's share price is $238.60. Synageva BioPharma Corp's median P/S value is $2.59. Therefore, Synageva BioPharma Corp's Price to Median P/S Value Ratio for today is 92.12.
During the past 13 years, the highest Price to Median P/S Value Ratio of Synageva BioPharma Corp was 51.17. The lowest was 0.11. And the median was 4.58.
Synageva BioPharma Corp's Median P/S Value for today is calculated as
|Median P/S Value||=||Total Annual Sales / Shares Outstanding||*||10-Year Median P/S Ratio|
|=||Revenue per Share (TTM)||*||10-Year Median P/S Ratio|
10-Year Median P/S Ratio is 14.37.
Synageva BioPharma Corp's revenue per share for the trailing twelve months (TTM) ended in Mar. 2015 was 0.07 (Jun. 2014 ) + 0.04 (Sep. 2014 ) + 0.04 (Dec. 2014 ) + 0.03 (Mar. 2015 ) = $0.18.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the companys value.
Synageva BioPharma Corp's Price to Median P/S Value Ratio for today is calculated as
|Price to Median P/S Value||=||Share Price||/||Median P/S Value|
Synageva BioPharma Corp Annual Data
Synageva BioPharma Corp Quarterly Data